Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea

Published:2009 Issue:2 Volume:41 Page:67
ISSN:1598-2998
Container-title:Cancer Research and Treatment
language:en
Short-container-title:Cancer Res Treat

Author:

Hong Min Hee¹²³,Kim Hyo Song¹²³,Kim Chan¹²³,Ahn Jung Ryun¹²³,Chon Hong Jae¹²³,Shin Sang-Joon¹²³,Ahn Joong-Bae¹²³,Chung Hyun Cheol¹²³,Rha Sun Young¹²³

Affiliation:

1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

2. Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.

3. Yonsei Cancer Center, Yonsei University Health System, Seoul, Korea.

Publisher

Korean Cancer Association

Subject

Cancer Research,Oncology

Link

http://www.e-crt.org/upload/pdf/crt-41-67.pdf

Reference16 articles.

1. Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World

2. Cancer Statistics, 2005

3. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

4. Sunitinib: From Rational Design to Clinical Efficacy

5. Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma;Journal of Cancer;2023

2. High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma;Cancers;2022-12-03

3. Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib;Bosnian Journal of Basic Medical Sciences;2022-06-08

4. Comparative Evaluation of Safety and Efficacy of Alternate Schedule (AS) of Sunitinib in Asian and Non-Asian Patient Population for the Treatment of Metastatic Renal Cell Cancer (mRCC): A Meta-Analysis;Kidney Cancer;2022-03-15

5. Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma;Medicine;2021-08-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3